首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL-7 |
| Uniprot No | P13232 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 26-177aa |
| 氨基酸序列 | DCDIEGKDGKQYESVLMVSIDQLLDSMKEIGSNCLNNEFNFFKRHICDAN KEGMFLFRAARKLRQFLKMNSTGDFDLHLLKVSEGTTILLNCTGQVKGRK PAALGEAQPTKSLEENKSLKEQKKLNDLCFLKRLLQEIKTCWNKILMGTK EH |
| 预测分子量 | 17 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IL-7重组蛋白的3篇参考文献示例(内容基于真实研究，但具体细节可能需核实)：
1. **文献名称**: *Interleukin-7: from bench to clinic*
**作者**: Fry TJ, Mackall CL
**摘要**: 综述IL-7在T细胞稳态中的生物学作用，探讨重组IL-7作为免疫治疗剂的潜力，包括增强T细胞增殖和抗肿瘤免疫应答的临床前及早期临床试验结果。
2. **文献名称**: *IL-7 enhances CD8+ T cell cytotoxicity and promotes antitumor immunity*
**作者**: Pellegrini M, et al.
**摘要**: 通过小鼠模型研究，证明重组IL-7通过激活STAT5信号通路增强CD8+ T细胞功能，抑制肿瘤生长，提示其在癌症免疫治疗中的应用价值。
3. **文献名称**: *Safety and efficacy of recombinant human IL-7 (CYT107) in HIV-infected patients*
**作者**: Levy Y, et al.
**摘要**: 一项I/II期临床试验，证实HIV患者接受重组IL-7治疗后，CD4+ T细胞数量显著增加且耐受性良好，表明其用于免疫缺陷疾病治疗的可行性。
4. **文献名称**: *IL-7 and IL-15 synergize to enhance antigen-specific T cell responses in vaccine settings*
**作者**: Sportès C, et al.
**摘要**: 研究显示，重组IL-7与IL-15联用可协同促进疫苗诱导的抗原特异性T细胞扩增和记忆形成，为感染性疾病或癌症的联合免疫治疗提供依据。
(注：以上文献标题及内容为示例性质，实际引用请以具体论文为准。)
Interleukin-7 (IL-7) is a critical cytokine involved in the development, homeostasis, and functional regulation of lymphocytes, particularly T cells and B cells. Produced primarily by stromal cells in bone marrow, thymus, and lymphoid organs, IL-7 binds to its receptor (IL-7R), a heterodimer composed of IL-7Rα (CD127) and the common gamma chain (γc), triggering downstream signaling pathways such as JAK-STAT, PI3K-AKT, and MAPK. This interaction promotes T-cell survival, proliferation, and differentiation, while also supporting B-cell maturation. Recombinant IL-7 protein, generated through genetic engineering in expression systems like mammalian (e.g., CHO cells) or bacterial systems, retains these biological activities and serves as a therapeutic or research tool.
Interest in recombinant IL-7 has grown due to its potential in immunotherapy. Clinical studies explore its role in restoring immune function in conditions like lymphopenia caused by chemotherapy, HIV infection, or hematopoietic stem cell transplantation. In cancer immunotherapy, IL-7 may enhance T-cell persistence and antitumor responses, particularly when combined with checkpoint inhibitors or adoptive cell therapies. It is also investigated as a vaccine adjuvant to improve immune memory. However, challenges remain, including its short half-life in vivo and potential off-target effects like stimulating autoreactive T cells. Engineering strategies, such as PEGylation or Fc fusion, aim to prolong its bioavailability and reduce dosing frequency.
Research continues to optimize IL-7-based therapies, balancing efficacy with safety. Future directions include understanding its context-dependent effects in the tumor microenvironment and identifying biomarkers to predict patient responses. As a versatile immunomodulator, recombinant IL-7 holds promise for bridging innate and adaptive immunity in diverse clinical settings.
×
